Sotarauta M - Search Results

1

Morphometry in human transitional cell bladder cancer. Nuclear area and standard deviation of nuclear area--relation to tumor grade (WHO) and prognosis.

Lipponen PK, Collan Y, Eskelinen MJ, Pesonen E, Sotarauta M. Lipponen PK, et al. Among authors: sotarauta m. Eur Urol. 1990;17(2):155-60. Eur Urol. 1990. PMID: 2311640

2

Potential of morphometry in grading transitional cell carcinoma of the urinary bladder.

Lipponen P, Simpanen H, Pesonen E, Eskelinen M, Sotarauta M, Collan Y. Lipponen P, et al. Among authors: sotarauta m. Pathol Res Pract. 1989 Nov;185(5):617-20. doi: 10.1016/S0344-0338(89)80205-5. Pathol Res Pract. 1989. PMID: 2626372

3

Comparison of morphometry and DNA flow cytometry with standard prognostic factors in bladder cancer.

Lipponen PK, Collan Y, Eskelinen MJ, Pesonen E, Sotarauta M, Nordling S. Lipponen PK, et al. Among authors: sotarauta m. Br J Urol. 1990 Jun;65(6):589-97. doi: 10.1111/j.1464-410x.1990.tb14826.x. Br J Urol. 1990. PMID: 2372672

4

Volume corrected mitotic index (M/V index) in human bladder cancer; relation to histological grade (WHO), clinical stage (UICC) and prognosis.

Lipponen PK, Collan Y, Eskelinen MJ, Pesonen E, Sotarauta M. Lipponen PK, et al. Among authors: sotarauta m. Scand J Urol Nephrol. 1990;24(1):39-45. doi: 10.3109/00365599009180358. Scand J Urol Nephrol. 1990. PMID: 2320971

5

DNA ploidy and S phase fraction in human bladder cancer. Relation to survival and histological grade (WHO).

Lipponen PK, Eskelinen MJ, Collan Y, Pesonen E, Ventilä T, Sotarauta M, Nordling S. Lipponen PK, et al. Among authors: sotarauta m. Urol Int. 1990;45(1):4-9. doi: 10.1159/000281649. Urol Int. 1990. PMID: 2305493

6

Prediction of superficial bladder cancer by histoquantitative methods.

Lipponen PK, Eskelinen MJ, Sotarauta M. Lipponen PK, et al. Among authors: sotarauta m. Eur J Cancer. 1990;26(10):1060-3. doi: 10.1016/0277-5379(90)90052-u. Eur J Cancer. 1990. PMID: 2148881

7

Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.

Rintala E, Jauhiainen K, Alfthan O, Hansson E, Juusela H, Kanerva K, Korhonen H, Permi J, Sotarauta M, Vaalasti T, et al. Rintala E, et al. Among authors: sotarauta m. Eur Urol. 1991;20(1):19-25. doi: 10.1159/000471653. Eur Urol. 1991. PMID: 1743226 Clinical Trial.

8

Prediction of T1-2 GI-II transitional cell bladder cancer; evaluation by histoquantitative methods.

Lipponen PK, Eskelinen MJ, Sotarauta M. Lipponen PK, et al. Among authors: sotarauta m. Scand J Urol Nephrol. 1991;25(2):129-34. doi: 10.3109/00365599109024547. Scand J Urol Nephrol. 1991. PMID: 1871558

9

Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer.

Kontturi M, Sotarauta M, Tammela T, Lukkarinen O, Romppainen ML, Gröhn P. Kontturi M, et al. Among authors: sotarauta m. Eur Urol. 1988;15(1-2):43-7. doi: 10.1159/000473393. Eur Urol. 1988. PMID: 2975221

10

Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study.

Jauhiainen K, Sotarauta M, Permi J, Alfthan O. Jauhiainen K, et al. Among authors: sotarauta m. Eur Urol. 1986;12(1):32-7. doi: 10.1159/000472573. Eur Urol. 1986. PMID: 3081351

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results